Overview

Dan Teleman has been Pharma Two B’s CEO since May 23 where he recently took the company public on Nasdaq through a merger with Hepion Pharmaceuticals and a concurrent PIPE. Dan has over 20 years of experience in the biotechnology industry. Prior to joining Pharma Two B, Dan was an Executive Partner at Israel Biotech Fund, a life science VC. Dan was Chairman of Tamarix Pharma, an early stage ophthalmology company developing novel anti apoptotic molecules and a Board member of 4C Biomed, an early stage immune-oncology company developing a novel antibody. Prior to that, Dan was the CEO of Atox Bio for 12 years, where he led the company through an NDA submission for Reltecimod, the first immunomodulator developed for NSTI and raised over $150M from top life science investors. Previously, Dan was the co-founder and CEO of PainReform, head of business development for Pharmos and held marketing and sales roles at Amgen. Dan is experienced in company formation, growth and fund raising. Dan holds an MBA from Duke University, Fuqua School of Business, and an MSc in Biochemical engineering from the Ben Gurion University.